A Giant Leap in the Treatment Options for Advanced Bladder Cancer
|
|
- Evan Hood
- 5 years ago
- Views:
Transcription
1 A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France
2 Clinical Features of Bladder Cancer Risk factors Smoking +++ Aniline and hydrocarbons Treatment-induced (alkylants, radiation) Age: 70% of patients >65 years old Often have smoking-induced comorbidities Moderate renal failure frequently found in patients Poor health status in metastatic setting Patients classified as fit or unfit 1 1. Galsky MD, et al. Lancet Oncol. 2011;12(3):
3 Overall survival (probability) Cisplatin/Gemcitabine Efficacy in Metastatic Disease Trial/Analysis N ORR (%) Median PFS, Months Median OS, Months Phase III study of classic MVAC vs cisplatin/gemcitabine 405 Classic MVAC: 46 Cisplatin/gemcitabine: 49 HR=0.97 (95% CI: ) P =.51 Classic MVAC: 8.3 Cisplatin/gemcitabine: 7.7 HR=1.09 (95% CI: ) P =.63 Classic MVAC: 15.2 Cisplatin/gemcitabine: 14.0 HR=1.09 (95% CI: ) P = GC MVAC Median OS months with GC vs 15.2 months with MVAC HR=1.09 (log rank P =.44) Time (months) GC, gemictabine/cisplatin; MVAC, methotrexate/vinblastine/doxorubicin/cisplatin; ORR, overall response rate; OS, overall survival; PFS, progression-free survival von der Maase H, et al. J Clin Oncol. 2000;18(17): von der Maase H, et al. J Clin Oncol. 2005;23(21):
4 Consensus Definition of Patients With Metastatic Urothelial Carcinoma Who are Unfit for Cisplatin-Based Chemotherapy Patients meeting at least one of the following are considered unfit WHO or ECOG performance status of 2, or Karnofsky performance status of 60%-70% Creatinine clearance (calculated or measured) less than 1 ml/s CTCAE version 4, grade 2 or above audiometric hearing loss CTCAE version 4, grade 2 or above peripheral neuropathy NYHA class III heart failure 30%-50% of metastatic patients are ineligible ( unfit ) for cisplatin CTCAE, Common Terminology Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; NYHA, New York Heart Association; WHO, World Health Organization Galsky MD, et al. Lancet Oncol. 2011;12(3):
5 EORTC 30986: Gemcitabine/Carboplatin vs M-CAVI in Cisplatin-Ineligible (Unfit) Urothelial Cancer Trial/Analysis N ORR, % Median OS, Months Median PFS, Months Phase III study of gemcitabine/carboplatin vs M-CAVI 626 Gemcitabine/carboplatin: 41.2 M-CAVI: 30.3 P =.08 Gemcitabine/carboplatin: 9.3 M-CAVI: 8.1 HR=0.94 (95% CI: ) P =.64 Gemcitabine/carboplatin: 5.8 M-CAVI: 4.2 HR=1.04 (95% CI: ) P =.78 EORTC, European Organisation for the Research and Treatment of Cancer; M-CAVI, methotrexate/carboplatin/vinblastine De Santis M, et al. J Clin Oncol. 2012;30(2):
6 Metastatic Disease: OS Rates for Patients Receiving Second-Line Vinflunine OS in the ITT population OS in the eligible population* Median OS (ITT) 6.9 months with VFL + BSC (n=253) versus 4.6 months with BSC (n=117) HR=0.88 (log rank P =.2613) Median OS (eligible) 6.9 months with VFL + BSC (n=249) versus 4.3 months with BSC (n=108) HR=0.78 (log rank P =.0227) *The eligible population excludes 13 patients who presented at least one major protocol violation at baseline Bellmunt J, et al. Ann Oncol. 2013;24(6):
7 Powles T, et al. Nature. 2014;515(7528):
8 IMvigor 210: Study Design Locally advanced or metastatic cancer of the bladder, renal pelvis, ureter, or urethra Predominant transitional cell histology Tumor tissue evaluable for PD-L1 testing No autoimmune disease or corticosteroid use Cohort 2 specific criteria: Progression during or following platinum (no restriction on number of prior lines of therapy) Creatinine clearance 30 ml/min ECOG PS 0-1 Cohort 1 (N 100): First-line cisplatin ineligible Cohort 2 (N 300): Disease progression during or following 1 platinumcontaining regimen Atezolizumab 1200 mg IV q 3 w Treatment until loss of clinical benefit (Cohort 2) Response assessment q 9 w (q 12 w after 54 w) Hypothesis: Response rate >10% (historical response rate in 2L) PS, performance status Rosenberg JE, et al. Lancet. 2016;387(10031):
9 What is the Response Rate? IC0 Group IC2/3 Group Response rate in unselected population: 15% PD-L1 expression on immune cells is associated with response But PD-L1 expression is not discriminant enough in advanced metastatic UBC UBC, urothelial bladder cancer Rosenberg JE, et al. Lancet. 2016;387(10031):
10 Is There Any Survival Improvement? The responses are durable Rosenberg JE, et al. Lancet. 2016;387(10031):
11 PD-1/PD-L1 Race Atezolizumab PD-L1 Phase III Durvalumab PD-L1 Phase I Avelumab PD-L1 Phase I Pembrolizumab PD-1 Phase III Nivolumab PD-1 Phase II
12 Patients With CR or PR at Best Response OS SLD Change From PD (%) 100 Similar Efficacy Plots for all of Them Atezolizumab Time Time Time CR, complete response; PD, progressive disease; PR, partial response; SLD, sum of the longest diameters Loriot Y. Unpublished data
13 Patients With CR or PR at Best Response OS SLD Change From PD (%) Similar Efficacy Plots for all of Them Durvalumab Time Time Time Loriot Y. Unpublished data
14 Patients With CR or PR at Best Response OS SLD Change From PD (%) Similar Efficacy Plots for all of Them Nivolumab Time Time Time Loriot Y. Unpublished data
15 Phase Where Are We? Atezolizumab Nivolumab Pembrolizumab Avelumab Durvalumab Phase III randomized trial Phase II single arm Phase III randomized trial Phase Ib Phase I/II Number of patients (153 patients 6 month follow-up 191 (103 eligible for efficacy analysis) Dosing 1200 mg q 3 w 3 mg/kg q 2 w 200 mg q 3 w 100 mg/kg q 2 w 10 mg/kg q 2 w ORR (ITT) 13.4% 19.6% 21.1% 17.6% 20.4% Duration of response 63% of responses ongoing at median follow-up of 17.3 months 77% of responses ongoing at median follow-up of 7 months 72% of responses ongoing at median follow-up of 14.1 months 89% of responses ongoing at median follow-up of 7.3 months 81% of responses lasting 6 months Median OS 8.6 months (ITT) 8.7 months 10.3 months Not reached (6-month OS = 54.5%) 14.1 months Median PFS 2.1 months 2.0 months 2.1 months 1.5 months 2.2 months Rate of grade 3/4 treatment-related AEs 20% 18% 13.5% (15% G3-5) 7.5% 6.8% AE, adverse event Powles T, et al. Abstract presented at: EACR-AACR-SIC Special Conference 2017; June 24-27, 2017: Florence, Italy. Abstract 606. Sharma P, et al. Lancet Oncol. 2017;18(3): Bellmunt J, et al. N Engl J Med. 2017;376(11): National Institutes of Health. Accessed November 23, Powles T, et al. J Clin Oncol. 2017;suppl 6S(35):Abstract 286.
16 KEYNOTE-045: Study Design DOR, duration of response; RECIST, Response Evaluation Criteria in Solid Tumors Bellmunt J, et al. N Engl J Med. 2017;376(11):
17 KEYNOTE-045: Baseline Characteristics Bellmunt J, et al. N Engl J Med. 2017;376(11):
18 KEYNOTE-045: Overall Survival Bellmunt J, et al. Presented at: SITC 2016; November 9-13, 2016: National Harbor, Maryland, United States. Abstract 470.
19 KEYNOTE-045: Response Rate Bellmunt J, et al. Presented at: SITC 2016; November 9-13, 2016: National Harbor, Maryland, United States. Abstract 470.
20 KEYNOTE-045: Treatment-Related Adverse Events Bellmunt J, et al. N Engl J Med. 2017;376(11):
21 IMvigor211: Atezolizumab vs Chemotherapy for Post-Platinum Advanced UC An open-label, 2-arm, randomized phase III trial Patients with metastatic or locally advanced UC after recurrence or progression following platinum-based chemotherapy; ECOG PS 0-1; evaluable tumor tissue for PD-L1 testing (N = 932) Atezolizumab 1200 mg q 3 w Investigator s Choice Paclitaxel 175 mg/m 2 q 3 w or Docetaxel 75 mg/m 2 q 3 w or Vinflunine 320 mg/m 2 q 3 w Treated until PD, unacceptable AE, or investigator decision Treated until PD or unacceptable AE Primary endpoints: OS Secondary endpoints: ORR, PFS, safety, pharmacokinetics UC, urothelial cancer National Institutes of Health. NCT Accessed November 23, 2017.
22 IMvigor211: Overall Survival for IC2/3 Population Events / Patients Median OS (95% CI) 12-Month OS Rate (95% CI) Atezolizumab 72/ months (8.6, 15.5) 46% (37, 56) Chemotherapy 88/ months (8.4, 12.2) 41% (32,50) IC, immune cell Powles T, et al. Abstract presented at: EACR-AACR-SIC Special Conference 2017; June 24-27, 2017: Florence, Italy. Abstract 606.
23 IMvigor211: Overall Survival for ITT Population Events / Patients Median OS (95% CI) 12-Month OS Rate (95% CI) Atezolizumab 324/ months (7.8, 9.6) 39% (35,44) Chemotherapy 350/ months (7.2, 8.6) 32% (28, 37) Median follow-up duration in ITT population: 17.3 months (range, 0 to 24.5 months) Powles T, et al. Abstract presented at: EACR-AACR-SIC Special Conference 2017; June 24-27, 2017: Florence, Italy. Abstract 606.
24 IMvigor211: Safety Summary AE, n(%) Atezolizumab (N = 459) All Cause Chemo (N = 443) Atezolizumab (N = 459) Treatment-Related Chemo (N = 443) All Grade AEs 438 (95%) 435 (98%) 319 (70%) 395 (89%) Grade 3 or 4 AEs 233 (51%) 249 (56%) 91 (20%) 189 (43%) Grade 5 AEs 17 (4%) 18 (4%) 1 (1%) 8 (2%) All Grade AESIs 139 (30%) 98 (22%) - - Grade 3 or 4 AESIs 37 (8%) 13 (3%) - - Grade 5 AESIs 0 1 (<1%) - - SAEs 188 (41%) 191 (43%) 72 (16%) 110 (25%) AEs leading to treatment disc 34 (7%) 78 (18%) 16 (3%) 63 (14%) AEs leading to dose modification, delay, or intertuption 134 (29%) 210 (47%) - - Rates of treatment-related AEs and AEs leading to discontinuation (any cause) were numerically lower in the atezolizumab arm AESI, adverse event of special interest; SAE, serious adverse event Powles T, et al. Abstract presented at: EACR-AACR-SIC Special Conference 2017; June 24-27, 2017: Florence, Italy. Abstract 606.
25 Open Questions How to identify responders? How to identify superprogressors? When should we treat patients? How long should we treat patients? How should we give ICI for frail patients? How to explain resistance and to overcome resistance? ICI, immune checkpoint inhibitor
26 Biomarker Assay Endpoint Drug Results IHC dako kit (22C3 clone) IHC Ventana (SP263) PD-L1 on IC Key Biomarkers Currently Assessed in UC to Predict Response to PD-1 or PD-L1 Blockade 1% of cell stained 25% of cell stained Pembrolizumab Durvalumab Higher expression associated with response Higher expression associated with response PD-L1 on TC IHC dako kit (22C3 clone) IHC dako kit (28-8) IHC Ventana (SP263) 1% of cell stained 1% vs 5% of cell stained 25% of cell stained Pembrolizumab Nivolumab durvalumab Higher expression associated with response Higher expression associated with response Higher expression associated with response T CD8 infiltration IHC Atezolizumab High T CD8 infiltration associated with response CD8 expression Gene expression High vs low Nivolumab High CD8 expression associated with response CXCL9 / CXCL10 expression Gene expression High vs low Nivolumab High expression associated with response Mutational load Exome sequencing Number of mutations/megabase Atezolizumab High mutation load associated with response TCGA classification Gene expression Luminal vs basal Atezolizumab Nivolumab Luminal 2 associated with better response to atezolizumab Basal 1 associated with better response to nivolumab INF-ɣ signature 25 gene expression High vs low Nivolumab Better response to nivolumab TCR sequencing DNA sequencing of the CDR3 region of the TCR beta chain Clonal dominance, clonal expansion and T-cell fraction Atezolizumab high T cell infiltration and clonality in the tumor plus peripheral expansion of dominant tumor-resident TCR clones associated with response No biomarker validated so far
27 Future Strategies for Immunotherapy Targeting several immune checkpoints Enhancing neoantigen expression Combination with targeted therapies, chemo, or IR Targeting T-cell metabolism and microenvironnement Reprogramming host microbiome Use earlier IR, ionizing radiation
28 Phase I/II Ongoing Second-Line Trials D4190C00010 (NCT ) Progression or recurrence of urothelial cancer following a first-line platinumcontaining regimen N = 167 Primary endpoints: Safety; Secondary Endpoints: ORR, PFS, DOR, and OS Durvalumab + tremelimumab STRONG (NCT ) Progression or recurrence of urothelial cancer following At least one first-line platinum-containing regimen Urothelial and non-urothelial N = 1200 R Durvalumab Durvalumab + tremelimumab Primary endpoint: Safety; Secondary endpoint: OS BISCAY (NCT ) Progression or recurrence of urothelial cancer following a firstline platinum-containing regimen PD-1 and PD-L1 naive N = 110 Somatic DNA Sequence R Control FGFR3 mut DDR+ Durvalumab Durvalumab + AZD4547 Durvalumab + olaparib Primary endpoints: Safety; secondary endpoints ORR and PFS
29 Phase I/II Ongoing Second-Line Trials CHECKMATE-032 (NCT ) 1 Progression or recurrence of urothelial cancer following a first-line platinum-containing regimen N = 196 Primary endpoint: ORR; secondary endpoints PFS and safety SAUL Study Design (NCT ) DANUBE (NCT ) Progression or recurrence of urothelial cancer following a first-line platinum-containing regimen No more than 2 prior lines of systemic chemotherapy N = 1000 R R n = 78 n = 26 n = 104 Nivolumab 3 mg/kg Nivolumab 1 mg/kg Ipilimumab 3 mg/kg Nivolumab 3 mg/kg Ipilimumab 1 mg/kg Atezolizumab Estimated timelines Estimated completion: May 2022 ORR = 26.5% ORR = 38.5% mpfs = 4.3m mos = 10.2m ORR = 26% mpfs = 2.6m mos = 7.3 Primary endpoint: Safety; secondary endpoints: ORR, OS, PFS, and quality of life MK (NCT ) Progression or recurrence of urothelial cancer following a first-line platinum-containing regimen PD-1 and PD-L1 naive N = 1200 R Pembrolizumab Pembrolizumab + epacadostat Primary endpoint: OS; Secondary endpoints: PFS and safety 1. Sharma P, et al. Presented at: SITC 2016; November 9-13, 2016: National Harbor, Maryland, United States. Abstract 449.
30 Current / Future Clinical Trials in UC NMIBC MIBC Metastatic UC 1 ère ligne Low Grade High Grade neoadjuvant Adjuvant fit unfit BCG refractory DANUBE (durvalumab, tremelimumab) MK (pembrolizumab) IMVIGOR 130 (atezolizumab CA (nivolumab, ipilimumab) Pembro + Epacadostat (KN672, phase III) Maintenance Avelumab (JAVELIN, phase III) 2 nde line Platinum-resistant Pembrolizumab (KEYNOTE 045, Phase III) Atezolizumab (IMVIGOR 211, Phase III) Pembrolizumab + Epacadostat (phase III)
31 A New Standard in First-Line? Imvigor 210: Overall Survival Investigator-Assessed Objective Response Rates Balar AV, et al. Lancet. 2017;389(10064):67-76.
32 KEYNOTE-052: Pembrolizumab as First-Line Patients (N = 370) Locally advanced/muc No prior chemotherapy ECOG PS 0-2 Ineligible for cisplatinbased chemotherapy: - CrCI <60 ml/min - ECOG PS 2 - Grade 2 neuropathy - NYHA class III Pembrolizumab 200 mg IV/Q3W Primary endpoints ORR ORR in PD-L1 + ORR = 29% in the whole cohort 370 patients ORR = 51% in PD-L1 expressing patients (PD-L1 >10%) INF-gamma Signature (18 genes) associated with ORR muc, metastatic urothelial cancer Balar AV, et al. Lancet Oncol Sep 26. [Epub ahead of print].
33 Ongoing First-Line Trials IMvigor130 (NCT ) 1L cisplatin-ineligible, locally advanced/metastatic ECOG PS 2 N = 1200 Co-primary endpoints: PFS and OS DANUBE (NCT ) 1L unresectable stage IV Eligible / ineligible for cisplatin-based chemotherapy N = 1004 Primary endpoint: OS R R Atezolizumab Platinum based chemo + atezolizumab Cisplatin + gemcitabine or carboplatin + gemcitabine Durvalumab + tremelimumab Durvalumab Cisplatin + gemcitabine or carboplatin + gemcitabine KEYNOTE-361 (NCT ) 1L unresectable or metastatic ECOG PS 2 N = 990 Co-primary endpoints: PFS and OS R Pembrolizumab + cisplatin/gemcitabine or Pembrolizumab + carboplatin/gemcitabine Pembrolizumab Cisplatin + gemcitabine or carboplatin + gemcitabine
34 Ongoing First-Line Trials CHECKMATE 901 (NCT ) Metastatic urothelial cancer Unfit or fit patients No chemotherapy in metastatic setting N = 897 R Nivolumab + ipilimumab Nivolumab + chemotherapy SOC Platinum-based chemotherapy Primary endpoint: OS and PFS in unfit patients; secondary endpoints: OS in all patients, ORR, safety JAVELIN (NCT ) Metastatic urothelial cancer CR, PR, SD upon 4-6 platinum-based chemotherapy N = 668 R Avelumab SOC: BSC Primary endpoint: OS; secondary endpoints: PFS, ORR, DOR, Safety Estimated completion: 2020 SOC, standard of care
35 Conclusions Immune checkpoint inhibitors approved in both first- and second-line therapy Level 1 evidence for pembrolizumab in second-line No data from randomized trials in first-line to date ~20% achieved response with PD-1/PD-L1 inhibitors Many combinations currently investigated
Options for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationLa realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga
La realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre. I +
More informationAVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationDisclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
More informationIntegrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
More informationAdvanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationUrothelial Carcinoma Highlights
Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation Disclosures Consulting or Advisory Role: Company:
More informationApproved checkpoint inhibitors in bladder cancer: which drug should be used when?
788310TAM0010.1177/1758835918788310Therapeutic Advances in Medical OncologyP Ghatalia, M Zibelman research-article20182018 Therapeutic Advances in Medical Oncology Review Approved checkpoint inhibitors
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationChallenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy
More informationNeoplasie uroteliali 2017 Highlights. Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Neoplasie uroteliali 2017 Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationExploring New Strategies in Bladder Cancer
Exploring New Strategies in Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, Genitourinary Translational Working Group Co-Director, Signal Transduction Program Smilow Cancer
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationEmerging Role of Immunotherapy in Advanced Urothelial Carcinoma
Current Oncology Reports (2018) 20:48 https://doi.org/10.1007/s11912-018-0693-y GENITOURINARY CANCERS (DP PETRYLAK AND JW KIM, SECTION EDITORS) Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationBiomarkers for immunotherapy in bladder cancer: a moving target
Aggen and Drake Journal for ImmunoTherapy of Cancer (2017) 5:94 DOI 10.1186/s40425-017-0299-1 REVIEW Biomarkers for immunotherapy in bladder cancer: a moving target David H. Aggen * and Charles G. Drake
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationI Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
I Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena XII Corso di aggiornamento AIRTUM per operatori dei Registri Tumori Reggio Emilia
More informationRoche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Media Release Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationTumori Genito-Urinari. Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini
Tumori Genito-Urinari Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini Prostate cancer treatment paradigm is evolving PROSTATE CANCER TREATMENT PARADIGMIS EVOLVING Non metatasticcrpc
More informationImmunotherapy in GU Cancers. Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore
Immunotherapy in GU Cancers Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore 1 Disclosures Speaker Bureau: Pfizer, J&J, Sanofi, Novartis, MSD Advisory Board/ Consultant: GSK,
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationOptimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy
More informationImmunotherapy and urothelial carcinoma. Yohann Loriot
Immunotherapy and urothelial carcinoma Yohann Loriot Immunothérapie en clinique : Cancers de vessie Où en sommes nous? Données phase I/II FDA «breakthrough designation» Prochaines étapes? Immunothérapie
More informationIMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Hematology/Oncology Fox Chase Cancer Center, Temple Health Neoadjuvant
More informationCancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable
Cancer Drugs Fund Managed Access Agreement Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data
More informationRECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer
RECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer IX CIS and EURASIA ONCOLOGY and RADOLOGY CONGRESS, ONCOUROLOGY SESSION 16 June 2016 Richard E Greenberg, MD, FACS Chief Urologic Oncology, Fox Chase
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationImmunoterapia nella malata avanzata. Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano
Immunoterapia nella malata avanzata Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano Five checkpoint inhibitors now approved for UC! BCG Atezolizumab (US/EU) (2L) Atezolizumab (US/EU)
More informationPD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer
Journal of Cancer Treatment and Research 2017; 5(5): 71-80 http://www.sciencepublishinggroup.com/j/jctr doi: 10.11648/j.jctr.20170505.11 ISSN: 2376-7782 (Print); ISSN: 2376-7790 (Online) PD1/PDL-1 Inhibitors:
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationNOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY. Jindřich Fínek LF UK a FN Plzeň
NOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY Jindřich Fínek LF UK a FN Plzeň 1 KARCINOM MOČOVÉHO MĚCHÝŘE INCIDENCE A MORTALITA 2 KARCINOM MOČOVÉHO MĚCHÝŘE ZASTOUPENÍ
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationPolicy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016
Name of Policy: Tecentriq (Atezolizumab) Policy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016 Background/Definitions: As a general rule, benefits are
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationRenal Cell (RCC) and Bladder Carcinoma (TCC)
Renal Cell (RCC) and Bladder Carcinoma (TCC) Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Disclosures Compensated lectures: BMS, Ipsen,
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationRoche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More information